Valuation: ConvaTec Group

Market Cap 5.74B 5.01B 4.6B 4.29B 8.14B 546B 8.27B 55.41B 21.48B 268B 21.54B 21.07B 923B P/E 2026 *
20.8x
P/E 2027 * 16.3x
Enterprise Value 6.94B 6.06B 5.56B 5.19B 9.84B 660B 10B 67B 25.97B 324B 26.04B 25.48B 1,116B EV / Sales 2026 *
2.7x
EV / Sales 2027 * 2.47x
Free-Float
95.19%
Yield 2026 *
2.67%
Yield 2027 * 2.99%
Manager TitleAgeSince
Chief Executive Officer 62 04/08/2025
Director of Finance/CFO 51 04/08/2025
Chief Operating Officer - 01/06/2026
Director TitleAgeSince
Director/Board Member 71 14/08/2017
Chairman 78 30/09/2019
Director/Board Member 62 02/03/2020
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 5.66B
+3.49%+2.32%-28.86%-12.49% 161B
+5.04%+3.32%-5.77%-5.57% 101B
+2.80%+3.33%+1.83%+54.09% 56.12B
+1.21%+1.27%+52.98%+49.67% 53.35B
+3.39%+4.43%-10.83%-40.12% 42.13B
+3.50%+14.35% - - 35.29B
+3.47%+3.79%-14.75%-44.56% 26.57B
+0.20%+5.53%+65.33%-4.37% 25.79B
+2.78%+3.61%-8.42%-3.01% 20.69B
Average +2.59%+4.18%+6.44%-0.80% 57.99B
Weighted average by Cap. +3.25%+3.31%-3.34%+0.13%

Financials

2026 *2027 *
Net sales 2.57B 2.24B 2.06B 1.92B 3.64B 244B 3.7B 24.79B 9.61B 120B 9.64B 9.43B 413B 2.74B 2.39B 2.2B 2.05B 3.88B 261B 3.95B 26.45B 10.25B 128B 10.28B 10.06B 440B
Net income 276M 241M 222M 207M 392M 26.31B 399M 2.67B 1.03B 12.9B 1.04B 1.01B 44.46B 359M 314M 288M 269M 510M 34.22B 518M 3.47B 1.35B 16.78B 1.35B 1.32B 57.83B
Net Debt 1.2B 1.05B 963M 898M 1.7B 114B 1.73B 11.59B 4.49B 56.02B 4.5B 4.41B 193B 1.03B 903M 830M 774M 1.47B 98.44B 1.49B 9.99B 3.87B 48.28B 3.88B 3.8B 166B
Logo ConvaTec Group
ConvaTec Group Plc specializes in the development, manufacturing and marketing of medical devices and products for ostomy care, wound care, and incontinence. The group also offers perfusion devices. Net sales break down by area of activity as follows: - wound care (30.9%): antimicrobial dressings, occlusive dressings, compression bandages, etc.; - ostomy care (27.7%): skin barriers, one-piece bags, 2-piece appliance bags, urostomy bags, etc.; - incontinence care (22%); - infusion (19.4%). At the end of 2025, the group operated 7 production sites worldwide. Net sales are distributed geographically as follows: Europe (29.6%), North Americas (55.7%) and other (14.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA